Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Aldeyra acquires Helio Vision

Executive Summary

Aldeyra Therapeutics Inc. is acquiring ophthalmic-focused biotech Helio Vision Inc. for $10mm up front in common stock (1.15mm shares) and another $2.5mm in stock two years from the date of closing. Helio could also receive another $12.5mm in stock for regulatory-based earn-outs.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Intra-Biotech Deal
    • Includes Contract
    • Acquisition of Private Biotech
    • Payment Includes Stock

Related Companies